SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DMTC or DIAMOND The Cat Coin is a viral meme coin on Solana Blockchain, Based in Thailand and Global and Based on a true story about my lovely cat(DIAMOND) and made by love, I just want my cat to be immortal in this whole world until I die that's a first idea of this project start. We're start from $2,000 Market cap and hit All time high at $10.9 million, please come to check our project and let's DMTC get list on Coingecko to let's everyone in this whole world know DMTC.

DIAMOND The Cat Coin

DIAMOND The Cat Coin ($DMTC.X) is trending as community members highlight its potential for significant upward movement, referencing signals of building energy and a possible breakout. The coin is being touted as a potential hidden gem, with many encouraging others to buy and hold. Conversations suggest anticipation for a surge, with the community using phrases like "loading rockets" and "going to the moon."

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential to break through resistance levels and reach new all-time highs, with some anticipating a move towards $300. Bullish sentiment is fueled by news of Galaxy Digital's significant SOL purchases and the increasing adoption of Solana's ecosystem for payments and decentralized applications.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as community members highlight its charitable donations to dog shelters and its potential within the meme coin space on Solana. Many are drawn to its community-driven nature and are actively discussing its long-term prospects and comparing it to other meme coins like Doge and Shiba Inu. The conversation includes playful engagement with the 'What's UpDog?' joke, contributing to the coin's visibility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated discussions surrounding the shooting of Charlie Kirk, with community members debating the shooter's motives and political affiliations. Conversations range from accusations of left-wing radicalization to defenses of conservative values and broader discussions of political violence. Insiders keep selling shares, as users debate who exactly the stock is for.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending as the community discusses the implications of the upcoming KYC grace period expiration and its potential impact on token supply. Speculation around future exchange listings and frustration over unverified balances are also key talking points. Despite mixed sentiment, some community members remain optimistic, citing the project's long-term potential and unique approach to crypto mining.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community discusses the upcoming mainnet rollout and potential for a spot ETF. Frustration is also voiced regarding HBAR's performance compared to meme coins and other Hedera tokens, while some anticipate a run higher alongside XRP. Recent news includes the selection of Hedera by Wyoming to host its stable token.

$JINGLE  is a meme community on Solana, The project was fair-launched on Pump.fun, This is a purely community-driven project.  $JINGLE a community powered token celebrating global holidays!  With a dedicated team and a vibrant community, $JINGLE Token aims to bring joy and prosperity to holders while embodying the spirit of the internet's favorite amphibian. Jump on board and let's make waves in the crypto pond together!

Jingle

$JINGLE.X is trending as community members express excitement about its potential, with many encouraging others to buy the dip and "jingle all the way." There is excitement and anticipation for a significant price increase. Some users are suggesting to move profits into $RI.X.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

ASST is trending due to the completion of its merger with Strive Enterprises, creating a publicly traded Bitcoin treasury company. The community is buzzing about the potential for a short squeeze, driven by high short interest and the company's plans to accumulate Bitcoin. Discussions also revolve around the impact of the merger on share structure and future company direction.

Pump.fun

$PUMP.X is trending as the community discusses its potential as the next big mover in the crypto space, drawing comparisons to the 2021 Dogecoin frenzy. Bullish sentiment is fueled by the platform's revenue model and potential for high returns, though some caution against the risks associated with investing in meme coins.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors discuss its potential in augmented reality, with community members highlighting the upcoming Meta Connect event and the company's AI investments. Despite some concerns about spending and competition, there is optimism surrounding Meta's role in bridging the gap between current AI and future AR experiences. Some traders are also noting technical setups that could lead to short-term gains.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of immunomodulation required for Sarepta Therapeutics' gene therapy (SRPT) Elevidys.The FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy (DMD) patients on Elevidys, Citi said, as per TheFly. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.Citi has a ‘Sell’ rating and a $14 price target on <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> shares. On Stocktwits, retail sentiment around Sarepta fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:563/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_2_11_08_PM_png_5b28899976.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>Citi made the observations in light of the FDA’s recommendations for Rocket Pharmaceuticals (RCKT) made public earlier in the day.Rocket <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> earlier on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said.The agency allowed the trial to resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing and with an immunomodulatory regimen more closely reflecting the one administered in an early-stage study pediatric cohort.Sarepta, like Rocket Pharma, has been plagued by patient deaths. It's gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.SRPT stock is down by 83% this year and by about 86% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 

Equity

Rocket Pharmaceuticals, Inc. (RCKT) on Wednesday said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease.The hold, <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">imposed</a> roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold">said</a>. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.Rocket Pharma stock shot up 25% in Wednesday’s pre-market session following the development. On Stocktwits, retail sentiment around RCKT rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels.&nbsp;Danon disease is a rare, genetic disorder primarily affecting the heart, skeletal muscles, and sometimes the brain. It's characterized by weakening of the heart muscle, muscle weakness, and intellectual disability.Following the death of a patient, Rocket paused further dosing in the mid-stage study, and on May 23, the FDA placed a clinical hold on the trial to allow for further evaluation. The trial can now resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing, followed by additional patients to complete the trial. The low dose has been determined as most likely to confer the safety and efficacy identified in the low-dose early-stage study cohorts, the company said.Rocket also said that it will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting the one administered in the early-stage study pediatric cohort. Further updates about the mid-stage study can be expected following review of data from the next three patients, the company said.RCKT stock is down by 77% this year and by about 85% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rocket Pharma Stock Up 25% Pre-Market Today? 

The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

RCKT Stock Tanks on Patient Death in Danon Disease Study

Wall Street analysts issued a fresh round of ratings changes on Wednesday, including notable upgrades for State Street (STT) and FICO (FICO) and downgrades for Booz Allen (BAH) and Rocket Pharmaceuticals (RCKT), according to TheFly.Top 3 Upgrades:State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85. The brokerage sees the company as the biggest beneficiary among trust banks from the recent equity market rebound.<a href="https://stocktwits.com/symbol/STT">State Street’s stock</a> was up 0.71% in morning trade on Wednesday.JPMorgan upgraded Vail Resorts’ (MTN) shares to ‘Neutral’ from ‘Underweight,’ keeping the $167 target, citing improved risk-reward at current levels.&nbsp;The upgrade comes after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vail-resorts-brings-back-longtime-ceo-rob-katz/ch0odyHRbrF">announced</a> on Tuesday that Rob Katz will return as CEO, effective immediately, replacing Kirsten Lynch, who has served as chief executive for three years.<a href="https://stocktwits.com/symbol/MTN">Vail Resorts’ stock</a> rocketed 14.44% in morning trade on Wednesday.Baird shifted its outlook on FICO’s shares to a more bullish stance, raising the stock to ‘Outperform’ from ‘Neutral’ but with a lower price target of $1,900, down from $2,021. The brokerage said the stock’s recent sell-off, tied to regulatory risk, creates upside potential.<a href="https://stocktwits.com/symbol/FICO">Fico’s stock</a> traded up 6.3%&nbsp;on Wednesday morning.Top 3 Downgrades:Goldman Sachs cut its&nbsp;rating on Booz Allen’s stock to ‘Sell’ from ‘Neutral,’ trimming the price target to $94 from $108, citing limited medium-term growth and downside valuation risk.<a href="https://stocktwits.com/symbol/BAH">Booz Allen’s stock</a> fell 2.24% in morning trade on Wednesday.Meanwhile, TD Cowen downgraded Freshpet (FRPT) shares to ‘Hold’ from ‘Buy’, maintaining a price target of $96. The brokerage said slowing retail sales growth triggered the call.<a href="https://stocktwits.com/symbol/FRPT">Freshpet’s stock</a> was down 4.18%&nbsp;on Wednesday morning.&nbsp;Jefferies slashed its rating on Rocket Pharmaceuticals stock to ‘Hold’ from ‘Buy’ and the price target to $2.50 from $29, citing an FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">clinical hold</a> on a key gene therapy trial.&nbsp;<a href="https://stocktwits.com/symbol/RCKT">Rocket Pharmaceutical’s</a> stock was up 3.6% at the start of Wednesday’s session despite the bearish outlook.The broader market traded in the red as investors watched for Nvidia’s (NVDA) earnings after the closing bell. The SPDR&nbsp;<a href="https://stocktwits.com/symbol/SPY">S&amp;P 500</a> ETF Trust (SPY) fell 0.14%, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ</a> Trust (QQQ), which tracks the Nasdaq 100, edged 0.04% lower. The SPDR&nbsp;<a href="https://stocktwits.com/symbol/DIA">Dow Jones Industrial Average</a> ETF (DIA) was down 0.1%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/game-stop-stock-climbs-after-first-ever-bitcoin-buy-worth-half-a-billion/ch0oSz2RbsX">GameStop Stock Declines After First-Ever Bitcoin Buy Worth Half A Billion</a>

The Wall Street Bull statue in Manhattan. (Photo by Erik McGregor/LightRocket via Getty Images)

Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today

State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85.

Rocket Pharmaceuticals (RCKT) plunged nearly 63% on Tuesday, hitting an all-time low after the U.S. FDA placed a clinical hold on its gene therapy trial, RP-A501, for Danon disease following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-pauses-rocket-pharmaceuticals-gene-therapy-trial-after-patient-death/ch0V9xRRbrR">death</a> of a patient.The selloff marked the company's worst session on record.&nbsp;Despite the steep decline, retail investor sentiment remained notably bullish. Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers&nbsp;over the past 24 hours — the highest among healthcare stocks on Tuesday.<h3>Wall Street Turns Cautious</h3>According to The Fly, the incident prompted a wave of downgrades from major analysts:<ul style="list-style-type:circle;"><li>Morgan Stanley cut RCKT to 'Equal Weight' from 'Overweight' and slashed its price target from $42 to $7, which still implies more than 200% upside from current levels.</li><li>Leerink lowered its rating to 'Market Perform' from 'Outperform' with a new target of $8. The firm cited three overhangs: safety concerns, shaken investor confidence, and financial pressure.</li><li>TD Cowen downgraded the stock to 'Hold' from 'Buy,' citing unresolved safety risks related to thrombotic microangiopathies that preceded the addition of the C3 inhibitor.</li><li>Needham also moved to 'Hold' from 'Buy' and withdrew its $42 target, calling RP-A501 the company's "main value driver" but now fraught with uncertainty.</li></ul><h3>Retail Shrugs Off Worries</h3>Despite the institutional pullback, retail traders doubled down. Stocktwits sentiment turned 'extremely bullish,' with many users arguing that Rocket's broader pipeline remains compelling.<figure class="image"><img style="aspect-ratio:1322/862;" src="https://news.stocktwits-cdn.com/RCKT_chart_with_sentiment_meter_and_message_volume_as_of_May_27_png_0e99f740f3.webp" alt="RCKT chart with sentiment meter and message volume as of May 27.png" width="1322" height="862"><figcaption>RCKT chart with sentiment meter and message volume as of May 27. | source: Stocktwits</figcaption></figure>One optimist expects the stock to be "back over $4.50 (maybe $5) within 3 months."<stembedurl>https://stocktwits.com/srick2000/message/615977188</stembedurl>"For one moment, ignore the CV gene therapy, which is the cause of today's drop, and just look at the rest of the pipeline here. Particularly late-stage hematology," posted another, citing the firm's leadership, including CCO &amp; CMO Sarbani Chaudhuri, formerly with Johnson &amp; Johnson.<stembedurl>https://stocktwits.com/geegor/message/615978028</stembedurl>RCKT shares gained about 3% in after-hours trading following the plunge in the regular session.The episode echoes a March setback for&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-therapeutics-stock-has-a-nightmarish-week-after-dmd-patient-death/ch78AvoRbPU">Sarepta Therapeutics</a> (SRPT), when a patient receiving its approved Duchenne muscular dystrophy therapy died from liver failure.&nbsp;As Barron's&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barrons.com/articles/gene-therapy-trial-death-rocket-stock-7aee984c?mod=md_stockoverview_news">noted</a>, such high-profile incidents have made gene therapy stocks increasingly unpalatable for many investors, despite the field's early promise.<a href="https://stocktwits.com/symbol/RCKT">Rocket Pharma shares</a> are now down over 80% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trader watching stocks crash on screen - stock photo. 

Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery

Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers.

Shares of Rocket Pharmaceuticals, Inc. (RCKT) traded 64% lower in Tuesday’s pre-market trading session after the U.S. Food and Drug Administration (FDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp">placed</a> a clinical hold on its trial related to investigational gene therapy for Danon disease called RP-A501, following the death of a patient.The patient was part of the Phase 2 trial of RP-A501. They experienced an unexpected Serious Adverse Event (SAE) involving clinical complications related to a capillary leak syndrome (CLS), which led to their passing.CLS is a condition where fluid and proteins leak out of the small blood vessels and into surrounding tissues, causing dangerously low blood pressure, fluid buildup in the body, and other complications.Rocket Pharma said it is conducting a comprehensive root cause analysis and is in active dialogue with the FDA.While the company voluntarily paused dosing in the study after the death of the patient, the FDA on May 23 also placed a clinical hold on the trial to allow further evaluation, the company said.Rocket Pharmaceuticals said that it is working with the FDA to ensure the safety of all study patients and resume the trial “as expeditiously as possible,” but stopped short of providing a timeline for the resumption of trials.The company also said that it expects its existing resources to be sufficient to fund operations into 2027. Rocket had cash, cash equivalents, and investments of $318.2 million at the end of the first quarter.On Stocktwits, retail sentiment around Rocket Pharmaceuticals jumped from ‘bearish’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_8_29_26_AM_png_8a7c609af6.webp" alt="RCKT's Sentiment Meter and Message Volume as of 8:30 a.m. ET on May 27, 2025 | Source: Stocktwits" width="626" height="65"><figcaption>RCKT's Sentiment Meter and Message Volume as of 8:30 a.m. ET on May 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the drop in share price over the news could result in a strong entry point.<stembedurl>https://stocktwits.com/TheCatalystCalendar/message/615894941</stembedurl><a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> is down by over 50% this year and more than 70% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-vnvc-open-vaccine-manufacturing-in-vietnam/ch0VBtPRbrb">Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish

Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible."

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

RCKT
Rocket Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RCKT News

RCKT Rocket Pharmaceuticals Inc